A farewell to Ozzy, Coke's sugar high, another vaccine shake-up: The week in review
Health Secretary Robert F. Kennedy Jr. took another step toward overhauling the nation's vaccine policy when he approved the removal of thimerosal, a mercury-based preservative, from all flu vaccines despite widespread agreement in the medical community that the preservative is safe. Kennedy signed off on a recommendation from the Advisory Committee on Immunization Practices, a panel he replaced with his own appointed members in June, to stop distributing vaccines containing thimerosal, which has long been targeted by anti-vaccine groups.
An operatic honor for Melania
Republican lawmakers are working on a Kennedy Center production of their own: renaming the center's Opera House to the 'First Lady Melania Trump Opera House.' The House Appropriations Committee, whose spending bill funds the iconic performing arts venue in Washington, voted 33-25 for the change. Lawmakers have already agreed to spend $256.7 million on improvements to the center sought by President Donald Trump, who ousted much of the Kennedy Center's board after he took office and appointed himself chairman. He has criticized some of the center's performances and said in one visit that he 'never liked 'Hamilton' very much.'
A sweet twist to the Cola wars
Cane sugar: It's the real thing. A Coca-Cola made with cane sugar − not high-fructose corn syrup − is coming to the United States this fall, the company announced, just like the Coke you find overseas, including Mexico. (The long-running debate over which tastes better, U.S. Coke or Mexican Coke, has been a fierce one). The news doesn't come as a compete surprise; President Donald Trump had made a case for cane sugar Coke on social media in mid-July − 'You'll see. It's just better!' Also, not to be outdone, Pepsi announced it is launching Pepsi Prebiotic Cola this fall, in Original Cola and Cherry Vanilla, containing 5 grams of cane sugar and 3 grams of prebiotic fiber.
Ozzy Osbourne, the 'Prince of Darkness,' is dead
The heavy metal world has lost one of its most beloved characters, Ozzy Osbourne, at age 76, only weeks after reuniting with his original band, Black Sabbath, in England for a farewell show. Osbourne, who was infamous for his hard living (and for biting the head off a bat), exploded into stardom in a solo career and later branched into reality TV with MTV's 'The Osbournes' in the early 2000s. In 2020, he revealed he had Parkinson's disease. In a just-announced new memoir, 'Last Rites,' arriving Oct. 7, Osbourne says: 'Look, if it ends tomorrow, I can't complain. I've been all around the world. … I've done good, and I've done bad. But right now, I'm not ready to go anywhere.'
Remembering Ozzy Osbourne: Life on the 'Crazy Train': The metal icon through the years
All bets for 2026 are on Scottie Scheffler
Scottie Scheffler, fresh off a dominating win at the British Open July 20, is at the top of his game, and you can expect he'll be there for awhile. Scheffler, 29, who also captured the PGA Championship in May and now needs only a U.S. Open victory to enter the elite group of golfers who have won the sport's grand slam of all four major championships, is now the odds-on favorite to win every major in 2026, according to BetMGM. Declared the gaming venture's Matt Wall: 'The comparisons with Tiger Woods certainly don't look out of place right now.' − Compiled by Robert Abitbol
This article originally appeared on USA TODAY: A farewell to Ozzy, Coke's sugar high, the flu fight: Week in review
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
25 minutes ago
- Yahoo
As Senate race heats up, political expert cautions candidates about going too far to the right
There is still more than a year from the 2026 midterm election, but in battleground Georgia the race for Senate is heating up. U.S. Rep. Mike Collins officially announced on Monday that he is running for Senate, as Georgia Insurance Commissioner John King just last week announced he was suspending his campaign in the race. Collins now joins fellow Republican U.S. Rep. Buddy Carter in the race to unseat Democratic incumbent Sen. Jon Ossoff. 'So, in these primaries, you tend to have to go pretty far to the right,' University of North Georgia political science professor Nathan Price told Channel 2's Richard Elliot. Both Collins and Carter are trying to court the GOP base as both men hope to get President Trump's endorsement. Price isn't surprised that both men are racing to the right. RELATED STORIES: Insurance Commissioner John King suspends campaign for U.S. Senate Gov. Kemp announces decision on Senate run in 2026, ending speculation With Brian Kemp not running for Senate, which Georgia Republicans could challenge Jon Ossoff? He thinks it's necessary to win the GOP primary but cautions that going too far right could turn off moderate voters in places like Cobb and North Fulton counties, places where voters like Republican Gov. Brian Kemp but don't much care for Trump. 'If you move too far to the right where you are not able to win those highly educated, suburban voters in those swing states, it makes the math very difficult,' Price said. Kemp reportedly told the Republican Senate campaigns he wouldn't endorse any of them, something that may have led to King's exit from the race last week. Kemp reportedly plans to endorse his longtime family friend Derek Dooley once Dooley decides if he wants to run. Either way, the Republicans could be in for a messy and expensive primary - something they wanted to avoid. 'The Republicans to have a good shot at this seat want to avoid a messy primary fight that causes them to spend a lot of resources before they even get their chance at that general election,' Price said. Elliot reached out to people close to Dooley to see if he could get a hint of when and if he may make a decision to run. So far, he hasn't heard back from them.
Yahoo
25 minutes ago
- Yahoo
Jobs data: Why this expert expects a weakening labor market
The labor market is in focus as investors are set to get fresh jobs data throughout the week. The Burning Glass Institute director of economic research, Guy Berger, joins Market Domination Overtime to discuss how several policies coming out of the Trump administration are putting pressure on the labor market, including immigration changes and tariffs. To watch more expert insights and analysis on the latest market action, check out more Market Domination Overtime here.
Yahoo
25 minutes ago
- Yahoo
Bristol Myers, Bain Capital form new company to develop immunology drugs
(Reuters) -Drugmaker Bristol Myers Squibb and private equity firm Bain Capital will launch an independent company focused on developing immunology drugs, backed by Bain's $300 million financing round, the companies said on Monday. The new company will work on five experimental drugs licensed from Bristol Myers, including a late-stage lupus treatment and a mid-stage psoriasis drug that has shown promise in trials. Bristol Myers will retain nearly 20% equity in the venture and is set to receive royalties and milestone payments based on the drugs' success. The collaboration allows the drugmaker to concentrate its immunology research on treatments aimed at resetting the immune system while ensuring the continued development of promising assets, the companies said. "These assets have significant potential, and we are confident that this new company will drive their development to ensure greater impact for patients," said Julie Rozenblyum, senior vice president of business development at Bristol Myers. Daniel Lynch, a seasoned pharmaceutical executive, will take on the roles of executive chairman and interim CEO of the new company, while Bristol Myers' chief research officer Robert Plenge is set to join the board alongside Bain Capital partners. Canada Pension Plan Investment Board also participated in the financing round. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
